Genetic immunization of mice with human tyrosinase-related protein 2: Implications for the immunotherapy of melanoma

International Journal of Cancer

Volumn 86, Issue 1, 2000, Pages 89-94

  Steitz, Julia ^a   Brück, Jürgen ^a   Steinbrink, Kerstin ^a   Alexander, Enk ^a   Knop, Jürgen ^a   Tüting, Thomas ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TYROSINASE RELATED PROTEIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DEPIGMENTATION; FEMALE; IMMUNIZATION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY;

ADENOVIRIDAE; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, NEOPLASM; AUTOANTIBODIES; BIOLISTICS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CROSS REACTIONS; FEMALE; H-2 ANTIGENS; HUMANS; IMMUNOTHERAPY, ACTIVE; MELANOMA, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; OXIDOREDUCTASES; PEPTIDE FRAGMENTS; PROTEINS; RECOMBINANT PROTEINS; TRANSFECTION; VACCINES, DNA; VITILIGO;

EID: 0034090894     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(20000401)86:1<89::AID-IJC14>3.0.CO;2-I     Document Type: Article

References (38)

1. BENNETT, S.R., CARBONE, F.R., KARAMALIS, F., FLAVELL, R.A., MILLER, J.F.A.P. and HEATH, W.R., Help for cytuloxic-T-cell responses is mediated by CD40 signalling. Nature (Lond.), 393, 478-480 (1998).
2. BLOOM, M.B., PERRY-LALLEY, D., ROBBINS, P.F., LI, Y., EL-GAMIL, M., ROSENBERG, S.A. and YANG, J.C., Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. exp. Med., 185, 453-459 (1997).
3. BROSSART, P., GOLDRATH, A.W., BUTZ, E.A., MARTIN, S. and BEVAN, M.J., Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J. Immunol., 158, 3270-3276 (1997).
4. CASTELLI, C., TARSINI, P., MAZZOCCHI, A., RINI, F., RIVOLTINI, L., RAVAGNANI, F., GALLINO, F., BELLI, F. and PARMIANI, G., Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-relaled protein-2 and gp100 melanoma antigens. J. Immunol., 162, 1739-1748 (1999).
5. CONDON, C., WATKINS, S.C., CELLUZZI, C.M., THOMPSON, K. and FALO, L.D., DNA-based immunization by in vivo transfection of dendritic cells. Nature (Med.), 2, 1122-1128 (1996).
6. FISHMAN, P., MERIMSKI, O., BAHARAV, E. and SHOENFELD, Y., Autoantibodies to tyrosinase: the bridge between melanoma and vitiligo. Cancer, 79, 1461-1464 (1997).
7. FONG, L., RUEGG, C.L., BROCKSTEDT, D., ENGLEMAN, E.G. and LAUS, R., Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J. Immunol., 159, 3113-3117 (1997).
8. GIANANI, R. and SARVETNICK, N., Viruses, cytokines, antigens, and autoimmunity. Proc. nat. Acad. Sci. (Wash.), 93, 2257-2259 (1996).
9. GROSS, D.M., FORSTHUBER, T., TARY-LEHMANN, M., ETLING, C, ITO, K., NAGY, Z.A., FIELD, J.A., STEERE, A.C. and HUBER, B.T., Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science, 281, 703-706 (1998).
10. HARDY, S., KITAMURA, M., HARRIS-STANSIL, T. DAI, Y. and PHIPPS, M.L., Construction of adenovirus vectors through Cre-lox recombination. J. Virol., 71, 1842-1849 (1997).
11. HEATH, W.R., KURTS, C., MILLER, J.F. and CARBONE, F.R., Cross-tolerance: a pathway for inducing tolerance to peripheral tissue antigens. J. exp. Med., 187, 1549-1553 (1998).
12. HIRSCHOWITZ, E.A., LEONARD, S., SONG, W., FERRIS, B., LEOPOLD, P.L., LEWIS, J.J., BOWNE, W.B., WANG, S., HOUGHTON, A.N. and CRYSTAL, R.G., Adenovirus-mediated expression of melanoma antigen gp75 as immunotherapy for metastatic melanoma. Gene Ther., 5, 975-983 (1998).
13. + T cells in the antitumor immune response. J. exp. Med., 188, 2357-2368 (1998).
14. KAMEYAMA, K., TAKEMURA, T., HAMADA, Y., SAKAI, C., KONDOH, S., NISHIYAMA, S., URABE, K. and HEARING, V.J., Pigment production in murine melanoma cells is regulated by tyrosinase, tyrosinase-related protein 1 (TRP1), DOPAchrome tautomerase (TRP2), and a melanogenic inhibitor. J. invest. Dermatol., 100, 126-131 (1993).
15. LOFTUS, D.J., CASTELLI, C., CLAY, T.M., SQUARCINA, P., MARINCOLA, F.M., NISHIMURA, M.I., PARMIANI, G., APPELLA, E. and RIVOLTINI, L., Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1 (27-35). J. exp. Med. 184, 647-657 (1996).
16. MAMULA, M.J., LIN, R.H., JANEWAY, C.A., JR. and HARDIN, J.A., Breaking T cell tolerance with foreign and self co-immunogens. A study of autoimmune B and T cell epitopes of cylochrome c. J. Immunol., 149, 789-795 (1992).
17. OLDSTONE, M.B., Molecular mimicry and immune-mediated diseases. PASEB J., 12, 1255-1265 (1998).
18. OSSENDORP, F., MENGEDE, E., CAMPS, M., FILIUS, R. and MELIEF, C.J., Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. exp. Med., 187, 693-702 (1998).
19. + T lymphocytes. Proc. nat. Acad. Sci. (Wash.), 96, 2982-2987 (1999).
20. OVERWIJK, W.W., TSUNG, A., IRVINE, K.R., PARKHURST, M.R., GOLETZ, T.J., TSUNG, K., CARROLL, M.W., LIU, C., MOSS, B., ROSENBERG, S.A. and RESTIFO, N.P., gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. exp. Med., 188, 277-286 (1998).
21. PARDOLL, D.M., Inducing autoimmune disease to treat cancer. Proc. nat. Acad. Sci. (Wash.), 96, 5340-5342 (1999).
22. PARKHURST, M.R., FITZGERALD, E.B., SOUTHWOOD, S., SETTE, A., ROSENBERG, S.A. and KAWAKAMI, Y., Identification of a shared HLA-A *0201-restricted T-cell epitope from the melanoma antigen tyrosinase-relaled protein 2 (TRP2). Cancer Res., 58, 4895-4901 (1998).
23. ROSENBERG, S.A., Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today, 18, 175-182 (1997).
24. ROSENBERG, S.A. and WHITE, D.E., Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. Emphasis Tumor Immunol., 19, 81-84 (1996).
25. SCHEIBENBOGEN, C., HUNSTEIN, W. and KEILHOLZ, U., Vitiligo-like lesions following immunotherapy with IFN alpha and IL-2 in melanoma patients. Europ. J. Cancer, 30A, 1209-1211 (1994).
26. SCHOENBERGER, S.P., TOES, R.E., VAN DER VOORT, E.I., OFFRINGA, R. and MELIEF, C.S., T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature (Lond.), 393, 480-483 (1998).
27. SCHREURS, M.W., DE BOER, A.J., FIGDOR, C.G. and ADEMA, G.J., Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection. Cancer Res., 58, 2509-2514 (1998).
28. SONG, Y.H., CONNOR. E., LI, Y., ZOROVICH, B., BALDUCCI, P. and MACLAREN, N., The role of tyrosinase in autoimmune vitiligo. Lancet, 344, 1049-1052 (1994).
29. + T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J. exp. Med., 183, 1965-1971 (1996).
30. TSUKAMOTO, K., JACKSON, I.J., URABE, K., MONTAGUE, P.M. and HEARING, V.J., A second tyrosinase-related protein, TRP-2, is a melanogenic enzyme termed DOPAchrome tautomerase. EMBO J., 11, 519-526 (1992).
31. TÜTING, T., GAMBOTTO, A., DE LEO, A.B., ROBBINS, P.D., LOTZE, M.T. and STORKUS, W.J., Induction of tumor anligen-specilic immunity using DNA immunization in mice. Cancer Gene Ther., 6, 73-80 (1999a).
32. TÜTING, T., GAMBOTTO, A., STORKUS, W.J. and DE LEO, A.B., Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor antigen β-galactosidase and the BALB/c Meth A p53 tumor-specific antigen. Gene Ther., 6, 629-636 (1999b).
33. WANG, R.F., APPELLA, E., KAWAKAMI, Y., KANG, X. and ROSENBERG, S.A., Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J. exp. Med., 184, 2207-2216 (1996).
34. WANG, R.F., JOHNSTON, S.L., SOUTHWOOD, S., SETTE, A. and ROSENBERG, S.A., Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33. J. Immunol., 160, 890-897 (1998).
35. WEBER, L.W., BOWNE, W.B., WOLCHOK, J.D., SRINIVASAN, R., QIN, J., MOROI, Y., CLYNES, R., SONG. P., LEWIS, J.J. and HOUGHTON, A.N., Tumor , immunity and autoimmunity induced by immunization with homologous DNA. J. clin. Invest., 102, 1258-1264 (1998).
36. WÖLFEL, T., VAN PEL, A., BRICHARD, V., SCHNEIDER, J., SELIGER, B., MEYER ZUM BÜSCHENFELDE, K.-H. and BOON, T., Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Europ. J. Immunol., 24, 759-764 (1994).
37. YOKOYAMA, K., SUZUKI, H., YASUMOTO, K., TOMITA, Y. and SHIBAHARA, S., Molecular cloning and functional analysis of a cDNA coding for human DOPAchrome tautomerase/tyrosinase-related protein-2. Biochim. biophys. Acta, 1217, 317-321 (1994).
38. ZEH, H.J., PERRY-LALLEY, D., DUDLEY, M.E., ROSENBERG, S.A. AND YANG, J.C., High Avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J. Immunol., 162, 989-994 (1999).